Page last updated: 2024-10-28

miltefosine and Carcinoma, Squamous Cell

miltefosine has been researched along with Carcinoma, Squamous Cell in 7 studies

miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.

Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)

Research Excerpts

ExcerptRelevanceReference
" In addition, at the highest dosage group in rats, an increase in white blood cell counts (WBC) was observed."2.67Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. ( Drogendijk, TE; Oosterom, R; Planting, AS; Pronk, LC; Stoter, G; Verweij, J, 1994)
"Miltefosine was highly active against the human KB tumour xenograft in nude mice, leading to growth inhibition as well as regression of large established tumours, which suggested that its mode of action was not mediated by the T cell system."1.28Investigation into the immunological effects of miltefosine, a new anticancer agent under development. ( Hilgard, P; Kampherm, E; Nolan, L; Pohl, J; Reissmann, T, 1991)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (71.43)18.2507
2000's1 (14.29)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Prieto, MD1
Uribe-Restrepo, AF1
Arcos, D1
Vargas, DA1
Mahieu-Renard, L1
Richard, MA1
Dales, JP1
Buscaylet, S1
Lagrassa, S1
Grob, JJ1
Pronk, LC1
Planting, AS2
Oosterom, R1
Drogendijk, TE1
Stoter, G3
Verweij, J3
Gandia, D1
Armand, JP1
Fu, D1
Shi, Z1
Wang, Y1
Planting, A1
van der Burg, M1
Hilgard, P1
Kampherm, E1
Nolan, L1
Pohl, J1
Reissmann, T1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705]Phase 3437 participants (Actual)Interventional2006-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Complete Clinical Response

"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment

Interventionparticipants (Number)
Miltefosine85
Glucantime®103
Thermotherapy86

Failure

At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment

Interventionparticipants (Number)
Miltefosine34
Glucantime®14
Thermotherapy42

Recurrence

Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment

InterventionParticipants (Number)
Miltefosine3
Glucantime®4
Thermotherapy6

Trials

3 trials available for miltefosine and Carcinoma, Squamous Cell

ArticleYear
Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma,

1994
Phase II study of oral miltefosine in patients with squamous cell head and neck cancer.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:5

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male

1993
A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
    Journal of cancer research and clinical oncology, 1992, Volume: 118, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colore

1992

Other Studies

4 other studies available for miltefosine and Carcinoma, Squamous Cell

ArticleYear
Case Report: Squamous Cell Carcinoma Referred for Mohs Surgery Found to be Cutaneous Leishmaniasis.
    The American journal of tropical medicine and hygiene, 2018, Volume: 99, Issue:6

    Topics: Antibodies, Protozoan; Antiprotozoal Agents; Carcinoma, Squamous Cell; Diagnosis, Differential; Fema

2018
[Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].
    Annales de dermatologie et de venereologie, 2005, Volume: 132, Issue:4

    Topics: Administration, Topical; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Leg;

2005
Bcl-2 plays a key role instead of mdr1 in the resistance to hexadecylphosphocholine in human epidermoid tumor cell line KB.
    Cancer letters, 1999, Aug-03, Volume: 142, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Design; Drug Resistance; Gene Expression; Gene

1999
Investigation into the immunological effects of miltefosine, a new anticancer agent under development.
    Journal of cancer research and clinical oncology, 1991, Volume: 117, Issue:5

    Topics: Animals; Antibody Formation; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Immuni

1991